| INTRODUCTION
Chronic liver disease such as chronic hepatitis C virus (HCV) infection is associated with inflammatory and fibrotic liver injuries. Early detection of fibrosis progression is crucial for disease management, since patients with chronic liver diseases have an increased risk for developing liver cirrhosis and associated complications including hepatocellular carcinoma. Although liver biopsy remains the reference standard for evaluating liver fibrosis, it is limited by sampling error and the risk of complications. 1, 2 Much attention has therefore been paid to the development of non-invasive methods to detect liver fibrosis. Measurement of liver stiffness by transient elastography is a widely accepted method for non-invasive liver disease staging and might be more representative of the entire organ compared to liver biopsy. 3 However, this technique is costintensive and its availability is usually limited to liver centres.
Although substantial effort has been invested in the development of tests which allow the non-invasive assessment of liver fibrosis, so far no single assay for fibrosis detection has gained clinical validity. Therefore, the search for non-invasive simple biomarkers which allow the close monitoring of fibrosis progression continues. [4] [5] [6] For several liver diseases there is emerging evidence that progression of liver fibrosis is associated with senescence of parenchymal and nonparenchymal liver cells. [7] [8] [9] [10] [11] [12] [13] Senescent cells are characterised by a sustained cell cycle arrest and enhanced activity of certain lysosomal enzymes, such as b-galactosidase, a-fucosidase or chitotriosidase. [14] [15] [16] Multiple mechanisms, including reactive oxygen species (ROS) production, genotoxic drugs, replicative stress and telomere shortening, can trigger cellular senescence resulting in a DNA damage response. [17] [18] [19] DNA lesions lead to the rapid phosphorylation of the histone variant c-H2AX by DNA damage-responsive kinases as well as the activation of p53 and downstream target genes, such as cyclin-dependent kinase (CDK) inhibitors. 20 CDK inhibitors, ie, p21, p27 and p16, induce cell cycle arrest and thereby inhibit proliferation. In addition, senescence is associated with characteristic epigenetic changes, such as recruitment of phosphorylated heterochromatin protein 1c (p-HP1c) into senescence-associated heterochromatin foci. 21 These foci form as a result of trimethylation of histone H3K9 and contribute to the repression of genes involved in proliferation.
During liver disease progression, senescence can be induced by telomere shortening or telemore-independent mechanisms as a consequence of DNA damage and increased cell cycle turnover. 11, 22, 23 Senescence in human liver diseases has been so far mainly assessed by detection of p21 in liver tissues. [8] [9] [10] [11] [12] [13] Although senescence appears as an almost universal feature of chronic liver diseases, it is unknown whether senescence limits or promotes disease progression. In this regard, different consequences of senescence for the outcome of fibrosis have been reported in mouse models. For instance, in the model of CCl 4 -induced liver damage hepatic stellate cell (HSC) senescence, which was attributed to replicative exhaustion, was shown to limit fibrosis progression. 24 In contrast, in human liver cirrhosis HSC senescence was not observed. 25 While the effects of senescence for resolution vs progression of fibrosis might depend on the type of liver injury, also various cell types have identified to undergo senescence. Thus, hepatocytes, cholangiocytes, hepatic stellate cells as well as immune cells may be the major senescent cell population in different models. 26 Clearly, in view of recent therapeutic efforts in developing senolytic therapies, understanding the mechanisms of cellular senescence is important and could extend therapeutic options for the treatment of chronic liver diseases.
In the present study, we investigated the role of senescence in patients with chronic HCV infection. Using multiple senescence
markers our results clearly demonstrate the occurrence of senescence in diseased liver which increased with fibrosis progression.
Interestingly, we identified T-lymphocytes as the major senescent cell population. Moreover, by non-invasive measurement of the senescence marker chitotriosidase in sera of HCV patients, we found that chitotriosidase activity significantly correlated with histological fibrosis stages and liver stiffness as assessed by transient elastography.
| PATIENTS AND METHODS

| Patients
We investigated sera from 61 patients (56% male, mean age 51.84 AE 1.28 years) with chronic HCV infection. Mean values of AST and ALT levels were 81.5 AE 8.9 U/L and 103.5 AE 9.5 U/L, respectively. Sera from 22 age-matched healthy individuals (41% male, mean age 50.0 AE 2.9 years) served as control for chitotriosidase measurement. Histological disease activity was assessed according to Ishak et al. 27 Fibrosis staging (F0-F4) was performed according to METAVIR. 28 Patients were divided into different fibrosis groups, ie, F0-1 (n = 18), F2-3 (n = 32) and F4 (n = 11 
| Immunohistochemical analyses
Paraffin sections from patients with chronic HCV infection and fibro- (1:50; Santa Cruz Biotechnology) staining was performed as described. 
| Serological detection of chitotriosidase levels
Quantitative measurements of chitotriosidase activity in sera of HCV patients (n = 61) and healthy controls (n = 22) were performed in duplicates using the fluorimetric chitotriosidase substrate (4-methylumbelliferyl-b-D-N,N',N''-triacetylchitotriose) assay according to the protocol of the manufacturer (Sigma-Aldrich).
| Statistical analysis
Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA) and SPSS 24 software (IBM Corporation, Armonk, NY, USA), respectively. For comparing senescence markers in liver tissues, we used unpaired t-test (equal distribution). Chitotriosidase activity was compared in patients and healthy controls using Mann-Whitney's U test (non-equal distribution). Regression analysis was performed to calculate the Spearman's rank correlation coefficient. Receiver operating characteristics (ROC) analysis was performed. Data are presented as box plot and whiskers analysis as well as means AE standard error of the mean (SEM).
A P-value of less than 0.05 was considered significant.
| RESULTS
| Expression of senescence markers in chronic HCV infection
Cellular senescence is typically associated with DNA damage and widespread heterochromatin formation. 20, 21 The DNA damage In contrast with p-HP1c expression that was weaker in F2-3 stages of fibrosis and further increased in liver cirrhosis, c-H2AX expression was already strongly pronounced in lower stages of fibrosis and therefore only slightly increased further in stage F4. 
T A B L E 1 Clinical characteristics of patients with different fibrosis stages (METAVIR F)
Characteristic
F0-F1 F2-F3 F4
| Increased senescence is associated with progressed fibrosis in chronic HCV infection
A typical hallmark of senescence is a permanent cell cycle arrest, which often results from DNA damage and the epigenetic silencing of proliferation-inducing genes. 21 We therefore investigated downstream effectors of senescence, such as p21, p27 and p16, which positive cells, P < 0.01). In contrast with p21 and p27, no significant differences in p16 expression could be detected between fibrosis stages F2-3 and F4. Thus, multiple markers of senescence revealed a considerable increase in senescent cells in fibrotic scars which correlated with progressed fibrosis stages.
| Senescence of T-cells increases with fibrosis progression in chronic viral hepatitis
Since senescence was mostly evident in nonparenchymal fibrotic scars and less detectable in hepatocytes, we analysed the cell types 
F I G U R E 2 Immunohistochemical detection of p21, p27 and p16 in healthy liver tissues and liver tissues from patients with chronic HCV infection and different fibrosis stages (A). In healthy liver, no or only marginal immunoreactivity for all cyclin-dependent kinase inhibitors was detected. Weak immunoreactivity for p21, p27 or p16 was detected in fibrotic areas of patients with low fibrosis stages (F0-1), whereas prominent staining could be demonstrated in liver sections with relevant fibrosis stages (F2-3) that was even more pronounced in cirrhotic liver tissues (F4). The percentage of positive cells was assessed by analysing four microscopic fields at 400 9 magnification (B). Expression of p21 and p27 significantly increased from F0-1 to F2-3 and to F4 as well as from F2-3 to F4 fibrosis stages. A significant difference of p16 levels was detected between liver tissues with no or minimal fibrosis and F2-3 fibrosis as well as liver cirrhosis. Representative examples of the different groups of patients are shown. *P < 0.05; **P < 0.01; n.s., nonsignificant 
| Senescence-associated chitotriosidase is increased in sera of patients with relevant liver fibrosis
Having demonstrated elevated expression of senescence markers in liver tissues with increasing fibrosis, we asked whether a non-invasive tool could assess senescence at relevant fibrosis stages. Chitotriosidase, a lysosomal enzyme, has been identified as a suitable senescence biomarker. Thus, it was previously shown that chitotriosidase activity is increased in supernatants of senescent cells, in mouse models of premature senescence or in sera of patients with age-related diseases. 16 Indeed, we detected significantly higher (P < 0.01) chitotriosidase activity (mean 617.4 AE 85.9 U/L) in sera from patients with chronic HCV infection (n = 61) compared to age-matched healthy control individuals (n = 22; mean 247.5 AE 53.2 U/L) ( Figure 5A ). We F2-3 to F4 . In cirrhotic livers a higher percentage of p16-positive T-cells was found compared to liver tissues with lower fibrosis stages which was significant between F4 and F0-1. *P < 0.05; **P < 0.01; n.s., nonsignificant combination with transient elastography might represent a reliable method for the non-invasive assessment of relevant fibrosis stages.
| DISCUSSION
Cellular senescence represents a stress-related response to liver injury that is characterised by a persistent cell cycle arrest. [17] [18] [19] In the present study, we demonstrate that senescence increases with fibrosis progression and is most pronounced in cirrhotic livers of HCV patients. We verified the presence of senescence by multiple markers, including DNA damage and epigenetic alterations as well as the expression of CDK inhibitors, which collectively reflect typical hallmarks of senescence. Finally, we demonstrate that patients with chronic viral hepatitis reveal elevated serum levels of chitotriosidase depending on their fibrosis stage.
Increased senescence has been reported in several chronic liver diseases. 26 However, whether senescence contributes to liver fibrosis or not, is controversial and may be dependent on the cause of fibrotic disease. In a model of CCl 4 -induced liver fibrosis it was demonstrated that mice lacking the senescence regulator p53 displayed a decreased number of senescent hepatic stellate cells (HSCs), which was associated with an increased fibrogenic response. 24 This finding would suggest that senescence of activated HSCs might limit fibrosis progression. In this context, stellate cell senescence has been attributed to the decreased synthesis of extracellular matrix and the resolution of fibrosis. In contrast, mice with deficient telomerase were also demonstrated to suffer from accelerated fibrosis, indicating a profibrotic role of senescence in chronic liver diseases. 34 In line with this finding is the recent observation of reduced liver fibrosis in p21-deficient mice. 35 Moreover, enhanced p21 expression of human hepatocytes has been associated with liver fibrosis. [8] [9] [10] 13 Previously, up-regulation of p21 was found in hepatocytes adjacent to activated HSC, which is in line with the observation that senescent liver cells are often located along fibrotic scars. 7, 10, 25 In contrast, in mouse models of CCl 4 -triggered fibrosis HSCs represent the major senescent cell population. 24 In our study, we found that Prediction of fibrosis stages ≥F2 by serum chitotriosidase levels (D). The ROC analysis indicates the threshold for chitotriosidase levels with the best compromise sensitivity/specificity to predict fibrosis stages ≥F2. ROC, receiver operating characteristics; AUC, area under the curve mononuclear cells, in particular CD3+ T lymphocytes. As assessed by p-HP1c, p27 or p16 detection, T-cell senescence in liver tissues correlated with the fibrosis stage. Thus, whereas hepatocytes represent the major cell type of senescence in alcoholic or non-alcoholic steatohepatitis, in chronic viral hepatitis senescence of immune cells apparently predominates. 10, 11, 22, 32 There is increasing evidence that senescence may occur in the immune system during chronic viral infection. 32 However, analysis of senescence in T-cells has been mainly restricted to peripheral lymphocytes, whereas no studies have yet examined senescence in intrahepatic immune cells. For instance, it was demonstrated that chronic infection of mice with lymphocytic choriomeningitis virus results in senescence of CD8+ T-cells. 36 Moreover, in patients infected with cytomegalovirus both peripheral CD4+ and CD8+ Tcells were found to have reduced telomere length. 37 Interestingly and consistent with our findings, in circulating CD4+ T-lymphocytes the telomere length apparently correlates with increased fibrosis and a poor clinical outcome of patients with chronic HCV infection. 22 Telomere shortening was not only described in peripheral lymphocytes of patients with chronic HCV but also with hepatitis B virus (HBV) infection. 38 In line with this observation, we also found enhanced T-cell senescence in liver tissues of HBV-infected patients which was associated with progressed fibrosis stages (data not shown).
It has been suggested that, because of their limited proliferative life span, chronic activation during persistent inflammation induces premature senescence in T-cells. 32 The persistent activation of immune cells in chronic infection has been also linked to impairment of T-cell function, commonly called T-cell exhaustion. 39 In addition, proinflammatory regulators, such as IFNa or p38, can inhibit telomerase, leading to enhanced telomere shortening and senescence. 33 Finally, it was argued that chronic inflammation triggers oxidative stress, which causes DNA damage, telomere dysfunction and cellular senescence. 40 The increased ROS production might further enforce senescence by enhanced autocrine and paracrine feedback mechanisms. 51 In pulmonary fibrosis, it was shown that the SASP of senescent fibroblasts is profibrotic. 52 However, it is also conceivable that spatiotemporal differences in senescence in different cell types trigger the secretion of distinct SASP components, which might explain the controversy concerning profibrotic vs fibrinolytic roles of senescence in liver fibrosis. Moreover, senescence can result in a pro-inflammatory and pro-proliferative microenvironment which might contribute to liver disease progression and associated complications independently from fibrosis development. 10, 26 Our present study also demonstrates that the serum levels of chitotriosidase might mirror the extent of liver fibrosis in agematched patients with chronic viral hepatitis. Chitotriosidase has been previously found to be secreted in a number of senescence models, such as late-passage presenescent human fibroblasts or bone-marrow cells of telomerase knockout mice. 16 Moreover, increased chitotriosidase activity has been identified in patients with chronic diseases associated with telomere shortening. 16 We found that patients with relevant fibrosis or liver cirrhosis revealed significantly higher chitotriosidase serum levels compared to patients with no or minimal fibrosis. 
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